249 related articles for article (PubMed ID: 29260925)
1. Effective management strategies for patients with marginal zone lymphoma.
Rosand CB; Valla K; Flowers CR; Koff JL
Future Oncol; 2018 May; 14(12):1213-1222. PubMed ID: 29260925
[TBL] [Abstract][Full Text] [Related]
2. Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy.
Ayyappan S; William BM
Curr Oncol Rep; 2018 Mar; 20(4):33. PubMed ID: 29572581
[TBL] [Abstract][Full Text] [Related]
3. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.
Arcaini L; Paulli M; Boveri E; Vallisa D; Bernuzzi P; Orlandi E; Incardona P; Brusamolino E; Passamonti F; Burcheri S; Schena C; Pascutto C; Cavanna L; Magrini U; Lazzarino M
Cancer; 2004 Jan; 100(1):107-15. PubMed ID: 14692030
[TBL] [Abstract][Full Text] [Related]
4. Risk-tailored treatment of splenic marginal zone lymphoma.
Castelli R; Balzarotti M; Salvi E; Simona Rossi R; Lambertenghi Deliliers G; Bergamaschini L; Gidaro A
Anticancer Drugs; 2022 Jan; 33(1):e36-e42. PubMed ID: 34407041
[TBL] [Abstract][Full Text] [Related]
5. Clinical presentation and management of marginal zone lymphomas.
Thieblemont C
Hematology Am Soc Hematol Educ Program; 2005; ():307-13. PubMed ID: 16304396
[TBL] [Abstract][Full Text] [Related]
6. Contemporary management of nodal and primary splenic marginal zone lymphoma.
Leslie LA; Feldman TA; McNeill A; Timberg M; Iida H; Goy AH
Expert Rev Hematol; 2019 Dec; 12(12):1011-1022. PubMed ID: 31619091
[No Abstract] [Full Text] [Related]
7. Management of Marginal Zone Lymphoma: A Canadian Perspective.
Peters A; Keating MM; Nikonova A; Doucette S; Prica A
Curr Oncol; 2023 Feb; 30(2):1745-1759. PubMed ID: 36826096
[TBL] [Abstract][Full Text] [Related]
8. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.
Conconi A; Raderer M; Franceschetti S; Devizzi L; Ferreri AJ; Magagnoli M; Arcaini L; Zinzani PL; Martinelli G; Vitolo U; Kiesewetter B; Porro E; Stathis A; Gaidano G; Cavalli F; Zucca E
Br J Haematol; 2014 Jul; 166(1):69-76. PubMed ID: 24673512
[TBL] [Abstract][Full Text] [Related]
9. Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Thieblemont C
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):371-378. PubMed ID: 29222281
[TBL] [Abstract][Full Text] [Related]
10. Marginal Zone Lymphoma: State-of-the-Art Treatment.
Sindel A; Al-Juhaishi T; Yazbeck V
Curr Treat Options Oncol; 2019 Dec; 20(12):90. PubMed ID: 31807935
[TBL] [Abstract][Full Text] [Related]
11. Marginal zone lymphomas: management of nodal, splenic, and MALT NHL.
Kahl B; Yang D
Hematology Am Soc Hematol Educ Program; 2008; ():359-64. PubMed ID: 19074110
[TBL] [Abstract][Full Text] [Related]
12. Nodal marginal zone lymphoma: Clinical features, diagnosis, management and treatment.
Tadmor T; Polliack A
Best Pract Res Clin Haematol; 2017; 30(1-2):92-98. PubMed ID: 28288722
[TBL] [Abstract][Full Text] [Related]
13. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database.
Olszewski AJ; Castillo JJ
Cancer; 2013 Feb; 119(3):629-38. PubMed ID: 22893605
[TBL] [Abstract][Full Text] [Related]
14. Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma.
Cavalloni C; Varettoni M; Rattotti S; Arcaini L
Expert Opin Pharmacother; 2021 Sep; 22(13):1643-1649. PubMed ID: 34120550
[No Abstract] [Full Text] [Related]
15. Non-MALT marginal zone lymphomas.
Thieblemont C
Ann Oncol; 2008 Jun; 19 Suppl 4():iv70-3. PubMed ID: 18519410
[No Abstract] [Full Text] [Related]
16. The many faces of marginal zone lymphoma.
Zinzani PL
Hematology Am Soc Hematol Educ Program; 2012; 2012():426-32. PubMed ID: 23233614
[TBL] [Abstract][Full Text] [Related]
17. [Splenic marginal zone B-cell lymphoma with epidermotropic skin involvement].
Gómez-de la Fuente E; Villalón LB; Calzado-Villarreal L; Pinedo-Moraleda F; López-Estebaranz JL
Actas Dermosifiliogr; 2012 Jun; 103(5):427-31. PubMed ID: 21885023
[TBL] [Abstract][Full Text] [Related]
18. Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
Cheah CY; Opat S; Trotman J; Marlton P
Intern Med J; 2019 Sep; 49(9):1070-1080. PubMed ID: 30816618
[TBL] [Abstract][Full Text] [Related]
19. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
20. Canine nodal marginal zone lymphoma: Descriptive insight into the biological behaviour.
Cozzi M; Marconato L; Martini V; Aresu L; Riondato F; Rossi F; Stefanello D; Comazzi S
Vet Comp Oncol; 2018 Jun; 16(2):246-252. PubMed ID: 29205839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
